Passion for Innovation. Compassion for Patients.™



Top Management Presentation

Financial Results for 2Q Fiscal 2012 (April 1 - September 30, 2012)

Thursday, November 1, 2012

Joji Nakayama, President and CEO



1st Half FY2012 proceeded roughly to plan Absolutely committed to achieve full-year targets: Net sales ¥980.0 billion Operating income ¥100.0 billion


Steady progress in major development projects

Ranbaxy's continuous growth and ongoing contribution to profit

Maintenance of ¥60 annual dividend

Financial Overview









Consolidated Income Statement					Ranbaxy Group				
		FY2011 2Q	FY2012 2Q	FY2012		FY2011 (Jan-Jun)	FY2012 (Jan-Jun)	FY2012 (Jan-Dec)	
		Results	Results	Forecast	Progress	Results	Results	Plan	Progress
Net Sa	ales	456.0	484.2	980.0	49%	78.6	107.7	179.0	60%
Cost of Sales		128.9	143.8	302.0	48%	39.5	40.9		
SG&A Expenses		265.0	283.3	578.0	49%	32.2	47.4		
R& Exp	D penses	84.1	87.2	188.0	46%	4.7	4.1		
Oth Exp	her penses	180.9	196.1	390.0	50%	27.5	43.2		
Operating Income		62.2	57.1	100.0	57%	6.9	19.4		
Ordinary Income		66.3	49.9	100.0	50%	10.0	12.0		
Net Income		37.0	24.4	50.0	49%	10.3	8.1		
Currency	USD/JPY (average)	79.81	79.42	80.00					JPY Bn
Rate	EUR/JPY (average)	113.78	100.64	100.00					4















Business Highlights





Highlights Japan



Steady achievement of existing mainstay product targets

- Olmetec · 46% of annual target achieved
 - Highest share growth rate in mono therapy market.
 - Continue to stronger prescription with lower dosage or higher dosage, and appeal its efficacy and durability by using evidence with Japanese patients
- Rezaltas

 Sales 34% higher than 2Q FY2011.
 Focus will be catch up from a delay in the annual target progress.
 - Accelerate for the patients with less effective by mono therapy to be introduced to prescribe

Other mainstays (Loxonin, Cravit, Mavalotin, etc.)

- Progress in 1st half is mostly according to plan.
- Continuous and steady activities as current promotions

Highlights Japan



Realize earlier popularization of new products

Memary • 41% of annual target achieved

- Accelerate promotion post the cancellation of dosage restriction period
- Raise rates of combined treatment with Donepezil by strengthening approach towards specialists, speed up acquisition of prescriptions.

Nexium

- Higher competition among general practitioner market
 - Corresponding with the cancellation of dosage restriction period from Oct., promote with extensive pharmaceuticals information to speed up the switch of prescriptions from PPI.

Ranmark

- Sales results and number of adopting hospitals are progressing as planned.
- Continually promote safety, efficacy, convenience of use.

Tenelia

- Using comprehensive sales capabilities, including distribution strategies, to ensure the market release smoothly.
 - Appealing to the once-a-daily dosage, early market penetration is planned.

Highlights North America & Europe



Daiichi Sankyo Inc. (DSI)

Olmesartan	 65% of annual target was achieved.
fuenchies	· Provent competing generics from encroaching

- franchise Prevent competing generics from encroaching by improved patients' supporting program
- Welchol
 This year's annual target is more than 14% higher than FY2011, and 50% has been achieved in the 1st half. Aiming to surely achieve the annual target.
- Effient

 Aiming to maximize sales, strong efforts will be continued. And by maximum using the acquired evidence, differentiate competing drugs among ACS-PCI patients and maximize the sales

Luitpold Pharmaceuticals Inc. (LPI)

Venofer • 47% of annual target was achieved.

- The aggressive sales of competitor, and the entry of competing generics have created a severe market, but we are absolutely committed to achieve the annual target
- Other
 · Aiming to quickly resolve the GMP issue and obtain approval of
 Injectafar

Daiichi Sankyo Europe (DSE)

Olmesartan franchise In the 1st half, 44% of annual target was achieved, which was within the expected range

 Aggressive expansion of prescription for combination drugs as Sevikar and Sevicar HCT


Sales of Major Products



	JPY Bn					
		FY2011	FY2012	FY2012		
		2Q Results	2Q Results	Forecast	Progress	
GIO	Olmesartan	123.8	120.8	237.0	51%	
Global	Prasugrel (alliance revenue)	4.5	6.5	-	-	N
	Loxonin	30.1	29.7	62.0	48%	1
	Cravit	16.8	16.5	37.0	45%	1
	Nexium	2.6	4.4	29.0	15%	
ر	Memary	3.9	10.8	26.0	41%	
Japan	Mevalotin	17.4	13.3	26.0	51%	
	Artist	12.4	11.2	21.0	54%	
	Omnipaque	11.9	10.2	18.0	57%	
	Calblock	6.4	5.5	13.0	43%	
	Urief	5.4	5.4	11.0	50%	
U.S.	Welchol	13.6	15.5	31.0	50%	
S.	Venofer	12.9	10.7	23.0	46%	
Cu	USD/JPY rrency (average)	79.81	79.42	80.00		
Rate EUR/JPY (average)		113.78	100.64	100.00]	

Prasugrel Global Sales

IDV D.



*Source: financial announcements of Lilly



RANBAXY

Response to U.S. FDA and U.S. Department of Justice

- **Taking solid steps under a consent decree conducted with FDA**
- Taking steps to finalize issues raised by DOJ. Settlement expenses to be within \$500 million provided for reserve thereof in FY2011

Achievements of FY2012

- Maximization of value of Atorvastatin
- Entered market with pioglitazone Authorized Generic
- Smooth operational startup and of newly built Mohali plant in India

Future measures

- To enter market with Valsartan FTF and others
- Shrinking derivatives position
- To smoothly enter market in U.S. with dermatology products



Edoxaban (DU-176b)

Aiming for Best in Class FXa inhibitor

Steady progress in ENGAGE AF-TIMI 48 study, HOKUSAI VTE phase 3 study

Prasugrel (CS-747)

Expectations of commercial release in Japan

- Acute Coronary Patients undergoing PCI
- For coronary heart disease patients undergoing elective PCI
- Estimated filing in FY2013

Ischemic cerebrovascular disease



Tivantinib (ARQ 197)

Speed up measures to secure indication

- Preparing phase 3 study for liver-cell cancer patients
- Proceeding with phase 2 study for colon cancer patients

Denosmab (AMG 162)

Osteoporosis, bound for approval and launch

- Japanese submission in March, 2012
- Studies for other indication ongoing Breast cancer adjuvant, Rheumatoid arthritis, Giant cell tumor

Future Schedule





Passion for Innovation. Compassion for Patients.™



Global Research & Development

Thursday, November 1, 2012

Glenn Gormley MD PhD

Global Head of R&D Senior Executive Officer

Major R&D Pipeline

Therapeutic area	Phase 1	Phase 2	Phase 3	Application
Cardiovascular- Metabolics	/ Selective PPAR-gamma modulator)	 CS-747 (US) (Prasugrel / Sickle cell disease / anti-platelet agent) CS-3150 (JP)	 DU-176b (Global) (Edoxaban / AF / oral factor Xa inhibitor) DU-176b (Global) (Edoxaban / VTE / oral factor Xa inhibitor) CS-747 (Global*) (Prasugrel / ACS-MM / anti-platelet agent) CS-747 (JP) (Prasugrel / PCI / anti-platelet agent) CS-747 (JP) (Prasugrel / ischemic stroke / anti-platelet agent) 	
Oncology	 U3-1565 (US/JP) (Anti-HB-EGF antibody) DS-2248 (US) (HSP90 inhibitor) DS-7423 (US/JP) (PI3K/mTOR inhibitor) ARQ 092 (US) (Akt inhibitor) DS-3078 (US/EU) (mTOR inhibitor) 	 ARQ 197 (US/EU) (Tivantinib / Met inhibitor) CS-1008 (Global) (Tigatuzumab / anti-DR5 antibody) DE-766 (JP) (Nimotuzumab / anti-EGFR antibody) CS-7017 (US/EU) (Efatutazone / PPAR-gamma agonist) U3-1287 (US/EU) (Anti-HER3 antibody) PLX4032 (US/EU) (Vemurafenib / BRAF inhibitor) PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor) 	 ARQ-197 (Global*) (Tivantinib / NSCLC / Met inhibitor) AMG 162 (JP) (Denosumab / breast cancer adjuvant / Anti-RANKL antibody) 	
Others	 CS-8958 (Laninamivir / anti-influenza / Outlicensing with Biota) DS-8587 (Anti-bacterial) CS-4771 (Anti-sepsis) PLX5622 (Rheumatoid arthritis) CS-0777 (Immunomodulator) ASB17061 (Atopic Dermatitis) DS-7113 (Narcotic analgesic) 	 AMG 162 (JP) (Denosumab / rheumatoid arthritis / anti-RANKL anti-body) DS-5565 (Global) (Chronic pain / α2δ ligand) SUN13837 (US) (Spinal cord injury / Modulator of bFGF signaling system) 	 CS-8958 (JP) (Laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor) DD-723-B (JP) (Perflubutane / Contrast enhanced -ultrasonography for prostate tumor / ultrasound contrast agent) DR-3355 (JP) (Levofloxacin / anti-infection / new quinolone) 	 DD-723-B (JP) (Perflubutane / Contrast enhanced ultrasonography for breast lesions / ultrasound contrast agent) AMG 162 (JP) (Denosumab / osteoporosis / Anti-RANKL antibody)

The most advanced stages are described here in oncology area

Edoxaban (DU-176b) : Once Daily Oral Factor Xa Inhibitor



Development by Daiichi Sankyo globally

Indication	Summary
AF: ENGAGE AF-TIMI 48 Prevention of thromboembolic event	Phase 3 study, enrollment completed in Nov 2010
in atrial fibrillation Engage AF TIMI 48	Study to be completed by FY2012-end (Mar 2013)
VTE: HOKUSAI VTE Acute treatment and long-term	Phase 3 study, enrollment completed in Oct 2012
prevention of thromboembolic event in patient with DVT*/PE** HokusaiVTE	Study to be completed by FY2012-end (Mar 2013)
DVT-OS Prevention of post-surgical thromboembolic event	Launched in Japan on Jul 19, 2011

Edoxaban (DU-176b) : Competitive advantage



- The best dose-finding study in Phase 2
 - Ensures the best balance in efficacy and safety

• The best Phase 3 studies in FXa class

- The largest phase 3 studies
 - ENGAGE AF-TIMI 48 with over 21,000
 - HOKUSAI VTE with over 8,250
- 2 doses in ENGAGE AF-TIMI 48 (30mg, 60mg Once a daily) to provide flexible treatment options for patients
- The best design for study closing for ENGAGE AF-TIMI 48
- Accumulated safety data of about 70,000 from DVT-OS patients post launch of Lixiana in Japan

Prasugrel (CS-747) : Anti-platelet agent




Co-development with Ube Industries in Japan, with Eli Lilly outside of Japan

Indication	Summary
Japan domestic Phase 3 studies	Top line results of PRASFIT-ACS was announced in Sep 2012
-ACS-PCI*:PRASFIT-ACS -Elective-PCI -Ischemic stroke	Elective-PCI study to be completed by the end of FY2012
	Application planned in PCI in FY2013
	Ischemic stroke study to be completed in FY2014
Sickle Cell Disease in Pediatric Participants	Phase 2 study, started in Nov 2011
ACS-MM**: TRILOGY ACS Reduction of thrombotic cardiovascular events in acute coronary syndromes without PCI	Results presented at ESC in Aug 2012

*PCI : Percutaneous Coronary Intervention **MM : Medical Management

Prasugrel ACS-PCI Phase 3 in Japan PRASFIT - ACS

- Multicenter, randomized, double-blind, double-dummy, parallel group study
- Evaluation of efficacy and safety of prasugrel in patients with ACS(UA, NSTEMI, STEMI)



Daiichi-Sankyo



Co-development with ArQule globally, except Japan, Asia


Indication	Summary
HCC (Hepatocellular Carcinoma)	Results presented at ASCO in June 2012 Phase 3 study is currently being planned
CRC (Colorectal Cancer)	Phase 2 study ongoing
<i>NSCLC (Non-Small Cell Lung cancer): MARQUEE</i>	<i>Study has just been stopped based on the recommendation from Data Monitoring Committee, that the study will not reach its primary endpoint.</i>

Denosumab (AMG 162) : Anti- RANKL Antibody




Development by Daiichi Sankyo in Japan

Indication	Summary		
	NDA filed in Japan in Mar 2012		
Osteoporosis: DIRECT	Results presented at ASBMR in Oct 2012		
Breast cancer adjuvant	Phase 3 study ongoing		
Rheumatoid arthritis	Phase 2 study ongoing		
Giant cell tumor	Phase 2 study ongoing		
Bone metastasis	Launched in Japan on Apr 17, 2012 RANMARK (denosumab)		



Denosumab: DIRECT Study Lumbar Spine BMD Levels

BMD Percent Change From Baseline





	Doub	Open-label	
Adverse Event	Placebo (N=481) n (%)	Denosumab (N=475) n (%)	Alendronate (N=242) n (%)
All	446 (92.7)	448 (94.3)	229 (94.6)
Serious	68 (14.1)	66 (13.9)	30 (12.4)
Death	5 (1.0)	5 (1.1)	0 (0.0)
Leading to study discontinuation	2 (0.4)	5 (1.1)	2 (0.8)
Leading to discontinuation of IP	31 (6.4)	23 (4.8)	18 (7.4)
AEs of interest			
Hypocalcemia	0 (0.0)	2 (0.4)	2 (0.8)
Cellulitis	3 (0.6)	6 (1.3)	0 (0.0)
Infection	269 (55.9)	286 (60.2)	131 (54.1)
Cardiovascular disorder	63 (13.1)	68 (14.3)	21 (8.7)
Malignancy	11 (2.3)	9 (1.9)	2 (0.8)
Serious AEs of interest			
Cellulitis	0 (0.0)	0 (0.0)	0 (0.0)
Infection	7 (1.5)	5 (1.1)	3 (1.2)
Cardiovascular disorder	7 (1.5)	6 (1.3)	2 (0.8)
Malignancy	10 (2.1)	7 (1.5)	2 (0.8)

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1126

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.